Johnson & Johnson's recent quarterly report showed its MedTech segment sales fell short of Wall Street expectations, primarily due to pricing pressures in China and budget cuts in Europe. This shortfall caused the company's shares to decline, impacting investors who may now be eligible for a loss recovery review. The company’s international MedTech sales were essentially flat, and ongoing geopolitical and procedural volume challenges also contributed to the performance. Investors who suffered losses can submit their details for a potential securities claim investigation led by Levi & Korsinsky LLP.
Johnson & Johnson shares are trading at USD 253.69 on Pluang as of Oct 15, 2026 02:11 WIB, showing a 1-day gain of 2.04%. The stock's market capitalization stands at $599.12 billion, reflecting its large scale despite recent sales challenges. Pluang investors hold the stock for an average of 129 days, with a strong buy sentiment at 84% of order activity.
Johnson & Johnson reported strong Q3 earnings with a 6% sales increase and raised its full-year guidance, yet its stock dropped nearly 6% after a weak MedTech segment performance and costs from recent acquisitions. Despite the selloff, key drug sales...
Johnson & Johnson reported resilient sales growth and exceeded earnings expectations, driven by promising results in its Innovative Medicine segment and potential growth from its MedTech OTTAVA system. However, softness in profitability and ongoing r...
Johnson & Johnson reported a 6% revenue increase to $25.4 billion in Q3 2026, but earnings per share (EPS) declined 7.5% year-on-year, causing the stock to fall 5%. The company set aside $5.5 billion to resolve talc litigation, aiming for 95% plainti...
Johnson & Johnson reported third-quarter 2026 earnings per share of $2.59, surpassing analyst estimates of $2.52, with total revenue of $25.40 billion slightly above expectations. The company saw robust growth in its pharmaceutical segment, which off...
Johnson & Johnson's stock dropped 5% after reporting a 95.9% fall in net earnings caused by one-time charges including talc litigation costs, despite raising its full-year sales and adjusted earnings outlook. The company's Innovative Medicine divisio...
